{"id":"W2912199505","doi":"10.1016/j.clgc.2019.01.015","title":"COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; University of British Columbia","funders":"Janssen Biotech; National Cancer Institute; Eisai; Ipsen Biopharmaceuticals; Prometheus; North Carolina GlaxoSmithKline Foundation; Novartis; GlaxoSmithKline Australia; Exelixis; Sanofi; GlaxoSmithKline; Merck; Astellas Pharma Global Development; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Memorial Sloan-Kettering Cancer Center; Roche; Astellas Pharma US; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Pazopanib; Medicine; Post-hoc analysis; Oncology; Renal cell carcinoma; Internal medicine; Post hoc; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003644726,0.0004589839,0.001274108,0.0003056447,0.00009993524,0.00003477124,0.0002526013,0.0002056097,0.0007788789],"category_scores_gemma":[0.00002290391,0.0003447294,0.0006880552,0.0007849283,0.0001701303,0.0001679858,0.0001223321,0.0006636799,0.0003271025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003201994,"about_ca_system_score_gemma":0.0005462854,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006889783,"about_ca_topic_score_gemma":0.0000338615,"domain_scores_codex":[0.9965892,0.0002399366,0.0009145896,0.001044023,0.0005965795,0.0006156891],"domain_scores_gemma":[0.9973171,0.0003032134,0.0004035568,0.001097448,0.0003048737,0.0005738197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02663386,0.0009459763,0.9198226,0.0002052831,0.001487942,0.001843271,0.0001855496,0.0003072835,0.04211837,0.000004599122,0.0005425591,0.005902668],"study_design_scores_gemma":[0.007289181,0.009672205,0.9663489,0.0001304752,0.002556899,0.00006698779,0.0003341302,0.0002278466,0.007596399,0.000002295967,0.005301139,0.0004735709],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913148,0.00228932,0.00001283111,0.0009905858,0.0004282422,0.0009616609,0.00005489574,0.00009852988,0.003849113],"genre_scores_gemma":[0.9912603,0.0002437513,0.001114402,0.001628198,0.000597005,0.00009997638,0.0002226008,0.00007891658,0.004754813],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04652623,"threshold_uncertainty_score":0.9999005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03562386660572312,"score_gpt":0.3303050783745614,"score_spread":0.2946812117688382,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}